2024 / 06

Next Paper
DOI: 10.24075/brsmu.2024.072
Copyright: © 2024 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Interferon type I-expressing recombinant vaccinia virus as a platform for selective immunotherapy of glioblastoma and melanoma

Naberezhnaya ER1, Soboleva AV1, Vorobyev PO1, Vadekhina VV1, Yusubalieva GM1,2,3, Isaeva IV2, Baklaushev VP1,2,3,4, Chumakov PM1, Lipatova AV1
About authors

1 Engelhardt Institute of Molecular Biology, Russian Academy of Science, Moscow, Russia

2 Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Medical Biological Agency of Russia, Moscow, Russia

3 Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency, Moscow, Russia

4 Research Institute of Pulmonology of the Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Anastasia V. Lipatova
Vavilova, 32/1, Moscow, 119991, Russia; moc.liamg@vnaavotapil

About paper

Funding: the design of recombinant vaccinia virus strains was supported by the Russian Science Foundation grant No. 23-14-00370, and assessment of their properties in in vitro and in vivo models was supported by the Russian Science Foundation grant No. 22-64-00057; histologic and immunohistochemical assessment of tumor tissue was supported by FMBA of Russia.

Author contribution: Naberezhnaya ER — implementation of in vitro and in vivo experiments, manuscript writing; Soboleva AV — flow cytometry data acquisition, determining the cell line sensitivity to viruses; Vorobyev PO — designing recombinant viruses, production of preparative amounts of strains; Vadekhina VV — conducting in vivo experiments; Yusubalieva GM — interpretation of in vivo experimental data, manuscript writing; Isaeva IV — histologic and immunohistochemical assessment; Baklaushev VP — microscopy, describing histology and immunohistochemistry data, preparing a drawing, manuscript writing; Chumakov PM — manuiscript editing; Lipatova AV — study concept, general project management.

Compliance with ethical standards: the in vivo study was approved by the Ethics Committee of the Federal Scientific and Clinical Center of FMBA of Russia (protocol No. 7 dated 06 September 2022) and conducted in accordance with the the Eurasian Economic Commission Board’s guidelines No. 33 dated 14 November 2023 "On the Guidelines for handling laboratory (experimental) animals when conducting preclinical (non-clinical) studies". The number of animals per group was minimized; the subcutaneous tumor size in the groups did not exceed 2000 mm3. In vitro experiments involved the commercially available animal and human cell lines.

Received: 2024-11-26 Accepted: 2024-12-19 Published online: 2024-12-30
|
  1. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016; 107 (10): 1373–9.
  2. Shakiba Y, et al., Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy. Biochemistry (Mosc). 2023; 88 (6): 823–41.
  3. Shvalov AN, et al. Complete Genome Sequence of Vaccinia Virus Strain L-IVP. Genome Announc. 2016; 4 (3).
  4. Zonov E, et al. Features of the Antitumor Effect of Vaccinia Virus Lister Strain. Viruses. 2016; 8 (1).
  5. Hamad A, et al. Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies. Viruses. 2023; 15 (2).
  6. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther. 2009; 9 (9): 1163–76.
  7. Shakiba Y, et al. Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response. Mol Ther Oncolytics. 2023; 29: 158–68.
  8. Kirn DH, et al. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 2007; 4 (12): e353.
  9. Park BH, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008; 9 (6): 533–42.
  10. Shakiba Y, et al. Oncolytic Efficacy of a Recombinant Vaccinia Virus Strain Expressing Bacterial Flagellin in Solid Tumor Models. Viruses. 2023; 15 (4).
  11. Kochneva G, et al. Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression. Oncotarget. 2014; 5 (22): 11269–82.
  12. Tysome JR, et al. Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer. Hum Gene Ther. 2011; 22 (9): 1101–8.
  13. Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 2015; 15 (4): 231–42.
  14. Gastl G, Huber C. The biology of interferon actions. Blut. 1988; 56 (5): 193–9.
  15. Matveeva OV, Chumakov PM. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. Rev Med Virol. 2018; 28 (6): e2008.
  16. Pikor LA, Bell JC, Diallo JS. Oncolytic Viruses: Exploiting Cancer's Deal with the Devil. Trends Cancer. 2015; 1 (4): 266–77.
  17. Stojdl DF, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000; 6 (7): 821–5.
  18. Feola S, et al. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacol Ther. 2022; 236: 108103.
  19. Li R, et al. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat Rev Urol. 2021; 18 (9): 543–55.
  20. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015; 14 (9): 642–62.
  21. Davola ME, Mossman KL. Oncolytic viruses: how "lytic" must they be for therapeutic efficacy? Oncoimmunology. 2019; 8 (6): e1581528.
  22. Kirn DH, Thorne SH, Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009; 9 (1): 64–71.
  23. Vorobyev PO, et al. Comparative Efficiency of Accessible Transfection Methods in Model Cell Lines for Biotechnological Applications. Bulletin of RSMU. 2022; 3: 11–18.
  24. Kochneva G, et al. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy. Oncotarget. 2016; 7 (45): 74171–88.
  25. Lin AH, et al. Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity. J Virol. 2014; 88 (17): 10066–77.
  26. Samson A, et al. Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer Immunol Res. 2022; 10 (6): 745–56.
  27. Vasileva N, et al. The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma. Int J Mol Sci. 2024; 25 (8).
  28. Shakiba Y, et al. Comparison of the oncolytic activity of recombinant vaccinia virus strains LIVP-RFP and MVA-RFP against solid tumors. Bulletin of RSMU. 2023; 2: 4–11.